Please login to the form below

Not currently logged in
Email:
Password:

JAK1 inhibitor

This page shows the latest JAK1 inhibitor news and features for those working in and with pharma, biotech and healthcare.

BMS buoyed by FDA approval of Celgene’s myelofibrosis drug

BMS buoyed by FDA approval of Celgene’s myelofibrosis drug

Inrebic (fedratinib) is the second JAK inhibitor to be approved for myelofibrosis since Incyte’s Jakafi (ruxolitinib) was cleared by the FDA in 2011, and the first new treatment for the ... JAK1/2 inhibitor Jakafi is currently the only FDA-approved

Latest news

  • Gilead strikes $5.1bn deal to bolster ties with Galapagos Gilead strikes $5.1bn deal to bolster ties with Galapagos

    Big boost for Belgian biotech, without a buy-out. Gilead Sciences has agreed a $5.1bn deal to increase its stake in Galapagos, its partner for experimental JAK1 inhibitor filgotinib for ... well-regarded JAK1 inhibitor upadacitinib, which was filed for

  • FDA approves AbbVie’s psoriasis blockbuster-to-be Skyrizi FDA approves AbbVie’s psoriasis blockbuster-to-be Skyrizi

    phototherapy. The IL-23 inhibitor is expected to reach blockbuster sales, with analysts such as Clarivate Analytics predict the drug making $1.74bn in 2023 for AbbVie and its partner Boehringer ... That JAK1-selective inhibitor is intended to treat those

  • Gilead and Galapagos close in on filing for Xeljanz rival Gilead and Galapagos close in on filing for Xeljanz rival

    be plagued by the side effect problems that have held back some other drugs in the JAK inhibitor class. ... In FINCH 1, selective JAK1 inhibitor filgotinib was compared to AbbVie’s $18bn-a-year TNF antibody Humira (adalimumab) or placebo – given on

  • Gilead awaits CEO and readouts to revive fortunes Gilead awaits CEO and readouts to revive fortunes

    This puts more pressure on the success of pivotal data readouts from two potential blockbusters the first half of 2019: selonsertib, an ASK1 inhibitor being studied in patients with advanced fibrosis ... and the fatty liver disease non-alcoholic

  • European biosimilars hit AbbVie’s Humira revenues in Q4 European biosimilars hit AbbVie’s Humira revenues in Q4

    AbbVie filed its oral JAK1 inhibitor upadacitinib with the FDA and EMA in December, and the drug is expected to reach blockbuster status, after demonstrating superiority to Humira in trials.

More from news
Approximately 1 fully matching, plus 22 partially matching documents found.

Latest Intelligence

  • Orphan drugs and breakthrough therapies drive Cortellis Drugs to Watch 2019 Orphan drugs and breakthrough therapies drive Cortellis Drugs to Watch 2019

    Upadacitinib, from AbbVie, treats rheumatoid arthritis. Upadacitinib is an orally dosed inhibitor of an intracellular target called JAK1. ... The first-in-class inhibitor of hypoxia- inducible factor-prolyl hydroxylase, or HIFPH, was approved in December

  • Drug launches to watch in 2019 Drug launches to watch in 2019

    It also unveiled mid-stage data on its JAK1 inhibitor upadacitinib in atopic dermatitis, adding another clinical win to earlier successes in rheumatoid arthritis. ... t the only oral JAK inhibitor developer with its eye on that particular prize.

  • Deal Watch December 2015 Deal Watch December 2015

    Galapagos (NL). Gilead. Collaboration. licence. JAK1-selective inhibitor, filgotinib in phase II for RA and Crohn's disease . ... 825. Takeda (Respiratory). AstraZeneca. Acquisition - asset. AZ buys Takeda global respiratory business including PDE 4

  • Pharma deals during September 2013 Pharma deals during September 2013

    cancer, and AT13387, a second generation HSP90 inhibitor for the treatment of prostate and lung cancers. ... This deal is for a JAK1 inhibitor (GLPG0634). With both ALX-0061 and GLPG0634, AbbVie looks to be challenging two recent entrants to the RA space:

More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
COUCH.

WE ARE COUCH – a full service medical communications agency. We are a trusted partner; always striving to help make...

Latest intelligence

Empowered patients: shaking the foundations of healthcare
Precision medicine represents a new paradigm in healthcare.This new approach to treating and preventing disease views the patient holistically, analysing their genes, environment and lifestyle, and using this information to...
A uniquely English genomic medicine service
The UK National Health Service is developing one standardised approach to embedding precision medicine across the whole of England. Blue Latitude Health speaks to Dr Tom Fowler, Deputy Chief Scientist...
Blended Intelligence
Data is the most valued commodity of the modern world. For P&P it's all about the application....

Infographics